Develops targeted immunotherapies for cancer treatment by modulating the tumor microenvironment and enhancing immune response.
Werewolf Therapeutics, Inc., based in Cambridge, Massachusetts, is a pioneering biopharmaceutical company specializing in developing innovative cancer therapeutics. Established in 2017, Werewolf Therapeutics focuses on harnessing the body's immune system to combat cancer effectively. The company's approach revolves around its proprietary PREDATOR platform, which enables the creation of conditionally activated molecules. These molecules are designed to stimulate both adaptive and innate immunity, addressing the limitations associated with traditional proinflammatory immune therapies.
At the forefront of Werewolf Therapeutics' pipeline are promising lead product candidates. WTX-124 represents a conditionally activated Interleukin-2 INDUKINE molecule intended for treating advanced solid tumors. Additionally, WTX-330, another key candidate, is a conditionally activated Interleukin-12 INDUKINE molecule aimed at addressing relapsed or refractory advanced solid tumors or lymphoma. The company is also advancing WTX-613, a conditionally activated interferon alpha INDUKINE molecule designed to target both solid tumors and hematologic malignancies.
Werewolf Therapeutics' commitment to innovation and therapeutic advancement is underscored by its robust research and development efforts. With its headquarters strategically located in the biotech hub of Cambridge, Massachusetts, the company continues to push the boundaries of cancer treatment through groundbreaking science and a dedication to improving patient outcomes worldwide.